Asset Details
Do you wish to reserve the book?
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis
Do you wish to request the book?
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis
2018
Overview
Allogeneic hematopoietic cell transplantation (alloHCT) in older patients requires the weighing of risks and benefits for this potentially curative treatment while facing age-related limitations. Comprehensive geriatric and quality of life (EORTC QLQ C-30) assessements (CGA/QOL) in addition to disease-specific data were obtained in 108 consecutive patients (≥60 years) pre-HCT, at day +30, +100, and +180. Median follow-up of 106 patients alive at alloHCT was 43.5 months, median age 66 years (range 60–78). Eighty-six (81.2%) had advanced disease risk at HCT and 99 (91.7%) patients received reduced intensity conditioning (RIC). Median PFS was 13.4 months with 38.3% (95% CI: 28.6–47.4) alive and in remission at 2 years; median OS was 15.6 months with 43.9% (95% CI: 34.3–53.4) alive at 2 years. Prognostic factors for PFS were: age: HR 1.084 (95% CI: 1.032–1.137,
p
= 0.0011); HCT-CI: HR 1.13 (95% CI: 1.001–1.274,
p
= 0.048); for OS: age: HR 1.08 (95% CI: 1.031–1.139,
p
= 0.0017), Karnofsky Index: HR 0.97 (95% CI: 0.954–0.996,
p
= 0.02); EORTC QLQ C–30 fatigue: HR 1.09 (95% CI: 1.004–1.185,
p
= 0.039); Up-and-Go: HR 3.26 (95% CI: 1.001–10.6,
p
= 0.049). Follow-up assessments as time-dependent covariates were highly prognostic for OS and PFS. CGA/QOL confer additional prognostic utility in older alloHCT recipients.
